Document is current

Article History

Received: 8 October 2025

Accepted: 5 January 2026

First Online: 26 February 2026

Declarations

:

: Financial interests: J. Glajzer, J. Baum and H. Woopen have no relevant financial or non- financial interests to disclose. J. Sehouli has received speaker/consultant honoraria from Tesaro, Merck, Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma, GlaxoSmith, MSD, Eisai, Novocure, Oncoinvent, Tubulis, Immunogen, AbbVie, GSK, Bayer, Vifor Pharma, Hexal AG Novartis Pharma. J. Sehouli received research funding by Tesaro and MSD. J. Sehouli is an associate editor for gynecologic oncology at Archieves of Gynecology and Obstetrics. Grabowski received grants/research support by MSD, AstraZeneca, GSK, Abbvie, Esteve, Allergosan and honoraria or consultation fees by MSD, AstraZeneca, GSK, Abbvie, Esteve. E.I. Braicu received grants/research supports by AstraZeneca, Roche Diagnostics, GSK, NOGGO, Abbvie, Immunogen and honoraria or consultation fees by Abbvie, AstraZeneca, Immunogen, Myriad GSK.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Clinical Ethics Committee at Charité Universitaetsmedizin Berlin (No. EA2/014/24).

: Written consent was obtained from the patients via Tumorbank Ovarian Cancer (TOC).